Literature DB >> 21242894

Simian immunodeficiency virus macaque models of HIV latency.

Jesse D Deere1, Raymond F Schinazi, Thomas W North.   

Abstract

PURPOSE OF REVIEW: This review will focus on recent developments in several nonhuman primate models of AIDS. These models are being used to address viral latency and persistence during antiretroviral therapy in studies that are not feasible in humans. RECENT
FINDINGS: Further characterization of the various macaque models of AIDS has demonstrated that several aspects of viral persistence during antiretroviral therapy model HIV-1 infection in humans, including viral decay kinetics. Widespread distribution of viral RNA and viral DNA has been detected in many tissue organs. In addition, the brain has been identified as a site of persistent viral DNA.
SUMMARY: The macaque models of AIDS are well suited for addressing viral persistence during antiretroviral therapy, including viral latency, residual replication, and tissue organ distribution.

Entities:  

Mesh:

Year:  2011        PMID: 21242894      PMCID: PMC7734619          DOI: 10.1097/COH.0b013e32834086ce

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  40 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

3.  Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.

Authors:  Thomas W North; Koen K A Van Rompay; Joanne Higgins; Timothy B Matthews; Debra A Wadford; Niels C Pedersen; Raymond F Schinazi
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

4.  Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.

Authors:  Michael J Hofman; Joanne Higgins; Timothy B Matthews; Niels C Pedersen; Chalet Tan; Raymond F Schinazi; Thomas W North
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Authors:  Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

6.  In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells.

Authors:  Joseph K Wong; Matthew C Strain; Rodin Porrata; Elizabeth Reay; Sumathi Sankaran-Walters; Caroline C Ignacio; Theresa Russell; Satish K Pillai; David J Looney; Satya Dandekar
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

Review 7.  Evaluation of antiretrovirals in animal models of HIV infection.

Authors:  Koen K A Van Rompay
Journal:  Antiviral Res       Date:  2009-07-19       Impact factor: 5.970

8.  Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys.

Authors:  Maria Cecilia G Marcondes; Claudia Flynn; Salvador Huitron-Rezendiz; Debbie D Watry; Michelle Zandonatti; Howard S Fox
Journal:  AIDS       Date:  2009-06-19       Impact factor: 4.177

9.  A macaque model of HIV-1 infection.

Authors:  Theodora Hatziioannou; Zandrea Ambrose; Nancy P Y Chung; Michael Piatak; Fang Yuan; Charles M Trubey; Vicky Coalter; Rebecca Kiser; Doug Schneider; Jeremy Smedley; Rhonda Pung; Mercy Gathuka; Jacob D Estes; Ronald S Veazey; Vineet N KewalRamani; Jeffrey D Lifson; Paul D Bieniasz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

10.  Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.

Authors:  Jesse D Deere; Joanne Higgins; Elda Cannavo; Andradi Villalobos; Lourdes Adamson; Emilie Fromentin; Raymond F Schinazi; Paul A Luciw; Thomas W North
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

View more
  16 in total

Review 1.  The non-human primate model of tuberculosis.

Authors:  D Kaushal; S Mehra; P J Didier; A A Lackner
Journal:  J Med Primatol       Date:  2012-03-20       Impact factor: 0.667

Review 2.  Developing strategies for HIV-1 eradication.

Authors:  Christine M Durand; Joel N Blankson; Robert F Siliciano
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

Review 3.  HIV latency: experimental systems and molecular models.

Authors:  Shweta Hakre; Leonard Chavez; Kotaro Shirakawa; Eric Verdin
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

Review 4.  HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies.

Authors:  Paul R Gorry; Nicholas Francella; Sharon R Lewin; Ronald G Collman
Journal:  J Leukoc Biol       Date:  2013-10-24       Impact factor: 4.962

Review 5.  Targeted DNA mutagenesis for the cure of chronic viral infections.

Authors:  Joshua T Schiffer; Martine Aubert; Nicholas D Weber; Esther Mintzer; Daniel Stone; Keith R Jerome
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

6.  Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

Authors:  Thomas W North; Andradi Villalobos; Selwyn J Hurwitz; Jesse D Deere; Joanne Higgins; Payel Chatterjee; Sijia Tao; Robert C Kauffman; Paul A Luciw; James J Kohler; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

7.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

8.  Psychosocial Stress Alters the Immune Response and Results in Higher Viral Load During Acute Simian Immunodeficiency Virus Infection in a Pigtailed Macaque Model of Human Immunodeficiency Virus.

Authors:  Selena M Guerrero-Martin; Leah H Rubin; Kirsten M McGee; Erin N Shirk; Suzanne E Queen; Ming Li; Brandon Bullock; Bess W Carlson; Robert J Adams; Lucio Gama; David R Graham; Christine Zink; Janice E Clements; Joseph L Mankowski; Kelly A Metcalf Pate
Journal:  J Infect Dis       Date:  2021-12-15       Impact factor: 5.226

9.  Therapeutic imprinting of the immune system: towards a remission of AIDS in primates?

Authors:  Andrea Savarino; Enrico Garaci
Journal:  Retrovirology       Date:  2012-09-14       Impact factor: 4.602

Review 10.  Cellular and molecular mechanisms involved in the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Mark A Wainberg
Journal:  Retrovirology       Date:  2013-02-01       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.